Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Ottawa Marriott Hotel

Oct 29, 2018 7:00 AM - Oct 29, 2018 5:30 PM

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

Canadian Pharmacovigilance and Risk Management Strategies Conference

Session 4: Risk Management for Opioids: What’s New?

Session Chair(s)

Rania  Mouchantaf, PhD

Rania Mouchantaf, PhD

A/Executive Director, Marketed Pharmaceuticals Bureau, MHPD

Health Canada, Canada

The Government of Canada is committed to protecting the health and safety of all Canadians through a comprehensive, compassionate, collaborative and evidence-based approach to addressing problematic substance use. In June 2017, Health Canada proposed amendments to the Food and Drug Regulations that would enable the Minister of Health to require pharmaceutical manufacturers to have in place a risk management plan to monitor and mitigate risks associated with their opioid products, once they are on the market. This session will give an update on the progress of the measures to implement greater Risk Management for Opioids.


Andrew  Slot, PhD

Risk Management Plans for Opioids in Canada

Andrew Slot, PhD

Health Canada, Canada


Yola  Moride, PhD, FISPE

Canadian Databases for Mapping Out Opioid-Related Harms and Evaluating Effectiveness of Risk Minimization Measures

Yola Moride, PhD, FISPE

YolaRX Consultants, Canada


Ravi  Deshpande, PharmD

The US Approach to Opioids Risk Management: How Can Canada Use These Learnings

Ravi Deshpande, PharmD

McKesson Canada , Canada

Senior Vice President, Specialty Health

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.